|
Name |
1-Fluorotetradecane
|
Molecular Formula | C14H29F | |
IUPAC Name* |
1-fluorotetradecane
|
|
SMILES |
CCCCCCCCCCCCCCF
|
|
InChI |
InChI=1S/C14H29F/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15/h2-14H2,1H3
|
|
InChIKey |
YRDSYPITPPQNED-UHFFFAOYSA-N
|
|
Synonyms |
1-Fluorotetradecane; Tetradecyl fluoride; 73180-09-3; 593-33-9; Tetradecane, 1-fluoro-; Tetradecane, fluoro-(9CI); Fluorotetradecane; Myristyl fluoride; 1-Fluorotetradecan; EINECS 209-788-2; EINECS 277-311-5; 1-fluoro-tetradecane; Tetradecane, fluoro-; 1-Fluorotetradecane, 96%; SCHEMBL2281936; DTXSID10880875; ZINC2168598; MFCD00042114; AKOS015839789; DB-055730; FT-0607789
|
|
CAS | 593-33-9 | |
PubChem CID | 79053 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 216.38 | ALogp: | 7.2 |
HBD: | 0 | HBA: | 1 |
Rotatable Bonds: | 12 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 0.0 | Aromatic Rings: | 0 |
Heavy Atoms: | 15 | QED Weighted: | 0.361 |
Caco-2 Permeability: | -4.791 | MDCK Permeability: | 0.00002150 |
Pgp-inhibitor: | 0.001 | Pgp-substrate: | 0.003 |
Human Intestinal Absorption (HIA): | 0.002 | 20% Bioavailability (F20%): | 0.829 |
30% Bioavailability (F30%): | 0.977 |
Blood-Brain-Barrier Penetration (BBB): | 0.186 | Plasma Protein Binding (PPB): | 98.07% |
Volume Distribution (VD): | 3.664 | Fu: | 1.56% |
CYP1A2-inhibitor: | 0.383 | CYP1A2-substrate: | 0.206 |
CYP2C19-inhibitor: | 0.406 | CYP2C19-substrate: | 0.067 |
CYP2C9-inhibitor: | 0.134 | CYP2C9-substrate: | 0.925 |
CYP2D6-inhibitor: | 0.17 | CYP2D6-substrate: | 0.135 |
CYP3A4-inhibitor: | 0.186 | CYP3A4-substrate: | 0.064 |
Clearance (CL): | 5.415 | Half-life (T1/2): | 0.077 |
hERG Blockers: | 0.016 | Human Hepatotoxicity (H-HT): | 0.145 |
Drug-inuced Liver Injury (DILI): | 0.097 | AMES Toxicity: | 0.04 |
Rat Oral Acute Toxicity: | 0.692 | Maximum Recommended Daily Dose: | 0.274 |
Skin Sensitization: | 0.783 | Carcinogencity: | 0.419 |
Eye Corrosion: | 0.984 | Eye Irritation: | 0.989 |
Respiratory Toxicity: | 0.98 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000327 | 0.860 | D0Z5SM | 0.644 | ||||
ENC000423 | 0.792 | D07ILQ | 0.585 | ||||
ENC000426 | 0.745 | D05ATI | 0.552 | ||||
ENC000425 | 0.745 | D00AOJ | 0.528 | ||||
ENC000379 | 0.745 | D00FGR | 0.475 | ||||
ENC000422 | 0.729 | D0O1PH | 0.453 | ||||
ENC001240 | 0.729 | D0P1RL | 0.390 | ||||
ENC000466 | 0.717 | D05QNO | 0.379 | ||||
ENC000281 | 0.717 | D0Y8DP | 0.355 | ||||
ENC000380 | 0.704 | D0T9TJ | 0.343 |